| Literature DB >> 33113263 |
Weijia Xie1, Youhao Wang1, Yao Zhang1, Ying Xiang1, Na Wu1, Long Wu1, Chengying Li1, Tongjian Cai1, Xiangyu Ma1, Zubin Yu2, Li Bai3, Yafei Li1.
Abstract
Single-nucleotide polymorphisms (SNP) and long non-coding RNAs (lncRNAs) have been involved in the process of lung cancer. Following clues given by lung cancer risk-associated SNP, we aimed to find novel functional lncRNAs as candidate targets in lung cancer. We identified a lncRNA Oxidative Stress Responsive Serine Rich 1 Antisense RNA 1 (OSER1-AS1) through a lung cancer risk-associated SNP rs4142441. OSER1-AS1 was down-regulated in tumor tissue and its low expression was significantly associated with poor overall survival among non-smokers in non-small cell lung cancer (NSCLC) patients. Gain- and loss-of-function studies showed that OSER1-AS1 acted as a tumor suppressor by inhibiting lung cancer cell growth, migration and invasion in vitro. Xenograft tumor assays and a metastasis mouse model confirmed that OSER1-AS1 suppressed tumor growth and metastasis in vivo. The promoter of OSER1-AS1 was repressed by MYC, and the 3'-end of OSER1-AS1 was competitively targeted by microRNA hsa-miR-17-5p and RNA-binding protein ELAVL1. Our results indicated that OSER1-AS1 exerted tumor-suppressive functions by acting as an ELAVL1 decoy to keep it away from its target mRNAs. Our findings characterized OSER1-AS1 as a new tumor-suppressive lncRNA in NSCLC, suggesting that OSER1-AS1 may be suitable as a potential biomarker for prognosis, and a potential target for treatment.Entities:
Keywords: ELAVL1; OSER1-AS1; long non-coding RNA; miR-17-5p; non-small cell lung cancer
Year: 2021 PMID: 33113263 DOI: 10.1111/cas.14713
Source DB: PubMed Journal: Cancer Sci ISSN: 1347-9032 Impact factor: 6.716